- Home
- PRLD vs ARMP Comparison
PRLD vs ARMP Comparison
Compare PRLD & ARMP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PRLD
- ARMP
- Stock Information
- Founded
- PRLD 2016
- ARMP N/A
- Country
- PRLD United States
- ARMP United States
- Employees
- PRLD N/A
- ARMP N/A
- Industry
- PRLD Medicinal Chemicals and Botanical Products
- ARMP Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- PRLD Health Care
- ARMP Health Care
- Exchange
- PRLD Nasdaq
- ARMP Nasdaq
- Market Cap
- PRLD 50.1M
- ARMP 52.1M
- IPO Year
- PRLD 2020
- ARMP N/A
- Fundamental
- Price
- PRLD $0.88
- ARMP $1.91
- Analyst Decision
- PRLD Strong Buy
- ARMP Strong Buy
- Analyst Count
- PRLD 2
- ARMP 1
- Target Price
- PRLD $4.50
- ARMP $9.00
- AVG Volume (30 Days)
- PRLD 168.1K
- ARMP 36.4K
- Earning Date
- PRLD 08-11-2025
- ARMP 08-12-2025
- Dividend Yield
- PRLD N/A
- ARMP N/A
- EPS Growth
- PRLD N/A
- ARMP N/A
- EPS
- PRLD N/A
- ARMP N/A
- Revenue
- PRLD $7,000,000.00
- ARMP $4,699,000.00
- Revenue This Year
- PRLD N/A
- ARMP $8.43
- Revenue Next Year
- PRLD N/A
- ARMP N/A
- P/E Ratio
- PRLD N/A
- ARMP N/A
- Revenue Growth
- PRLD N/A
- ARMP 14.24
- 52 Week Low
- PRLD $0.61
- ARMP $0.90
- 52 Week High
- PRLD $6.80
- ARMP $3.42
- Technical
- Relative Strength Index (RSI)
- PRLD 48.33
- ARMP 52.83
- Support Level
- PRLD $0.85
- ARMP $1.74
- Resistance Level
- PRLD $1.25
- ARMP $2.00
- Average True Range (ATR)
- PRLD 0.10
- ARMP 0.15
- MACD
- PRLD -0.02
- ARMP -0.03
- Stochastic Oscillator
- PRLD 18.52
- ARMP 43.59
About PRLD Prelude Therapeutics Incorporated
Prelude Therapeutics Incorp is a clinical stage precision oncology company focused on discovering and developing small molecule therapies optimized to target the key driver mechanisms in cancers with high unmet needs. The company's pipeline includes four candidates currently in clinical development: PRT1419, a potent, selective inhibitor of MCL1; PRT2527, a potent and selective CDK9 inhibitor, PRT3645, a next-generation CDK4/6 inhibitor, and PRT3789 a first-in-class SMARCA2/BRM protein degrader.
About ARMP Armata Pharmaceuticals Inc.
Armata Pharmaceuticals Inc is a developer of pathogen-specific bacteriophage therapeutics for the treatment of antibiotic-resistant and difficult-to-treat bacterial infections using its proprietary bacteriophage-based technology. The company is developing and advancing a broad pipeline of natural and synthetic phage candidates, including clinical candidates for Pseudomonas aeruginosa, Staphylococcus aureus, and other pathogens. In addition, in collaboration with Merck, the company is developing proprietary synthetic phage candidates to target an undisclosed infectious disease agent.